Metabolize Inc

Based in California, US, Metabolize Inc. , was founded in 2024 by Dr. Morris Laster and Gideon Meir, and develops consumer metabolic health products based on Stanford Medicine-originated research. As of October 2026, the company is led by its CEO, Dr.

Morris Laster. On 15 October 2026, the company announced the completion of a USD 3. 2 million seed financing round led by Astanor, with participation from Maia Ventures, LongGame Venture and SOSV, to accelerate the commercialization of its Precision Metabolite™ Technology and support the development, validation and manufacturing of its metabolic health products. Metabolize develops consumer products based on its Precision Metabolite™ Technology, which uses naturally occurring metabolites identified through research led by Professor Jonathan Long at Stanford University and exclusively licensed to the company.

Its first product, NATLEAN, is a non-prescription dietary supplement combining N-acetyltaurine and taurine, designed to help reduce food noise, support appetite regulation and support long-term weight maintenance for people who are tapering off or have stopped GLP-1 medications. NATLEAN is offered directly to consumers through the company website. The company sells NATLEAN directly to consumers through its website, either as a one-time purchase or through recurring monthly and quarterly subscription plans. The company plans to use its October 2026 seed financing to accelerate the commercialization of its Precision Metabolite™ Technology and support the development, validation and manufacturing of its metabolic health products.

The company also plans to conduct a randomized, double-blind, placebo-controlled human trial of NATLEAN with 156 participants following funding, enrolling people within four weeks of stopping GLP-1 medications.